Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

343 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Olutasidenib: from bench to bedside.
Venugopal S, Watts J. Venugopal S, et al. Blood Adv. 2023 Aug 22;7(16):4358-4365. doi: 10.1182/bloodadvances.2023009854. Blood Adv. 2023. PMID: 37196640 Free PMC article. Review.
Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome.
DiNardo CD, Venugopal S, Lachowiez C, Takahashi K, Loghavi S, Montalban-Bravo G, Wang X, Carraway H, Sekeres M, Sukkur A, Hammond D, Chien K, Maiti A, Masarova L, Sasaki K, Alvarado Y, Kadia T, Short NJ, Daver N, Borthakur G, Ravandi F, Kantarjian HM, Patel B, Dezern A, Roboz G, Garcia-Manero G. DiNardo CD, et al. Among authors: venugopal s. Blood Adv. 2023 Jun 13;7(11):2378-2387. doi: 10.1182/bloodadvances.2022008378. Blood Adv. 2023. PMID: 35973199 Free PMC article.
The odyssey of pacritinib in myelofibrosis.
Venugopal S, Mascarenhas J. Venugopal S, et al. Blood Adv. 2022 Aug 23;6(16):4905-4913. doi: 10.1182/bloodadvances.2022007524. Blood Adv. 2022. PMID: 35622972 Free PMC article.
Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML.
Issa GC, Bidikian A, Venugopal S, Konopleva M, DiNardo CD, Kadia TM, Borthakur G, Jabbour E, Pemmaraju N, Yilmaz M, Short NJ, Maiti A, Sasaki K, Masarova L, Pierce S, Takahashi K, Tang G, Loghavi S, Patel K, Andreeff M, Bhalla K, Garcia-Manero G, Ravandi F, Kantarjian H, Daver N. Issa GC, et al. Among authors: venugopal s. Blood Adv. 2023 Mar 28;7(6):933-942. doi: 10.1182/bloodadvances.2022008316. Blood Adv. 2023. PMID: 36322818 Free PMC article.
Impact of anticoagulation prior to COVID-19 infection: a propensity score-matched cohort study.
Tremblay D, van Gerwen M, Alsen M, Thibaud S, Kessler A, Venugopal S, Makki I, Qin Q, Dharmapuri S, Jun T, Bhalla S, Berwick S, Feld J, Mascarenhas J, Troy K, Cromwell C, Dunn A, Oh WK, Naymagon L. Tremblay D, et al. Among authors: venugopal s. Blood. 2020 Jul 2;136(1):144-147. doi: 10.1182/blood.2020006941. Blood. 2020. PMID: 32462179 Free PMC article.
Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study.
Bataller A, Montalban-Bravo G, Bazinet A, Alvarado Y, Chien K, Venugopal S, Ishizawa J, Hammond D, Swaminathan M, Sasaki K, Issa GC, Short NJ, Masarova L, Daver NG, Kadia TM, Colla S, Qiao W, Huang X, Kanagal-Shamanna R, Hendrickson S, Ravandi F, Jabbour E, Kantarjian H, Garcia-Manero G. Bataller A, et al. Among authors: venugopal s. Lancet Haematol. 2024 Mar;11(3):e186-e195. doi: 10.1016/S2352-3026(23)00367-8. Epub 2024 Feb 2. Lancet Haematol. 2024. PMID: 38316133 Clinical Trial.
343 results